Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Price:
401.08 USD
0.23%
Market Closed
Updated:
May 6, 2024
Vertex Pharmaceuticals Inc
Cash from Financing Activities
|
Vertex Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
MRNA
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Vertex Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
-562.2m
USD
-562.2m
USD
Based on the financial report for Dec 31, 2023, Vertex Pharmaceuticals Inc's Cash from Financing Activities amounts to -562.2m USD.
What is Vertex Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-51%
-51%
Over the last year, the Cash from Financing Activities growth was -730%. The average annual Cash from Financing Activities growth rates for Vertex Pharmaceuticals Inc have been -4% over the past three years , -51% over the past five years .
You don't have any saved screeners yet
